狄诺塞麦效果怎样呢？

(denosumab) is a monoclonal antibody that specifically targets receptor activator of nuclear factor i-κB ligand (RANKL). It can inhibit osteoclast activation and development, reduce bone resorption, and increase bone density. Denosumab was earlier used to treat osteoporosis in postmenopausal women with a higher risk of fractures, with good safety and efficacy. On May 27, 2019, denosumab was approved by the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or where surgical resection may cause severe functional disability, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and body weight >45 kg). Its current new indications are: prevention of bone-related events (SREs, including bone pain, pathological fractures, spinal cord compression, hypercalcemia, and bone complications requiring surgery or radiotherapy, etc.).

How effective is denosumab treatment?

In a study analysis, James et al. evaluated the effects of denosumab and zoledronic acid in the treatment of bone-related events in prostate cancer bone metastases, showing that compared with zoledronic acid, denosumab can significantly reduce the risk of bone-related events. A large phase III clinical trial in the United States for patients with newly diagnosed multiple myeloma showed that compared with zoledronic acid, denosumab is not inferior in preventing skeletal-related events and can improve the survival rate of patients, significantly reduce renal toxicity, and has good economic benefits.

(denosumab) can only be given by subcutaneous injection, not intravenous infusion, intramuscular infusion or intradermal injection. (2) Solid tumor bone metastasis: 120mg once every 4 weeks, injected subcutaneously in the upper arm, thigh or abdomen. (3) Giant cell tumor of bone: 120 mg once every 4 weeks, subcutaneous injection, and then 120 mg on d8 and d15 in the first month of treatment. (4) Administer calcium and vitamin D appropriately to prevent hypocalcemia.